
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is expected to have potential revenue of $540 million in the US, leading to a total enterprise value of $520 million. The acquisition of Galantos Pharma GmbH i.L. in early settlement provides for a simplified and streamlined royalty agreement and the company is sufficiently funded to reach profitability in the near- and medium-term. Risks include delayed market uptake and clinical setbacks, but we maintain our Buy rating and a 12-month price target of $18 based on continued commercial and financial progress.
Bears say
Alpha Cognition is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases with their current focus on commercializing ZUNVEYL, a differentiated treatment for Alzheimers disease. However, their financials may be hindered by the limited market for such treatments and the potential for cheaper generic alternatives. The company is making strides in clinical trials and expanding its evidence base, but the new appointment of a director with experience in successful company sales may indicate potential difficulties in achieving financial success.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares